Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Peptidyl-prolyl cis-trans isomerase FKBP11 (FKBP11)
- Target
- FKBP11
- Molecular classification
- Enzyme, Peptidyl-prolyl cis-trans isomerase, FK506-binding protein family, Endoplasmic reticulum translocon accessory protein
01
Overview
Peptidyl-prolyl cis-trans isomerase FKBP11 (FKBP11) is a member of the FKBP family of enzymes that catalyze the cis-trans isomerization of proline residues in polypeptide chains, a critical process in protein folding[2][6]. Unlike related family members, FKBP11 is a transmembrane protein localized in the endoplasmic reticulum (ER), where it functions as a translocon accessory factor, aiding the synthesis and biogenesis of secretory and membrane proteins with long ER-lumenal segments[1]. FKBP11 is most highly expressed in specialized secretory cells and is transcriptionally upregulated under conditions of ER stress[1]. It is implicated in bone formation, immune cell function (notably B-cell tolerance and plasma cell differentiation), and may play a role in diseases linked to defective protein folding and the secretory pathway[1][2]. Its enzymatic activity is inhibited by the immunosuppressant drugs FK506 (tacrolimus) and rapamycin (sirolimus)[2][6].
- Other names
- FKBP19FKBP-19FKBP-1119 kDa FKBP19 kDa FK506-binding proteinFK506-binding protein 11RotamasePPIase FKBP11UNQ336/PRO535
02
Mechanism of action
Immunosuppressants (FK506, rapamycin) inhibit FKBP11's peptidyl-prolyl isomerase activity by direct binding[2][6]
03
Biological functions
Protein foldingSecretory and membrane protein biogenesisEnzymatic prolyl isomerization (cis-trans isomerase)Regulation of secretory pathwayB-cell toleranceBone formationCardiac cell growthPlasma cell differentiationResponse to endoplasmic reticulum stress
04
Disease associations
Osteogenesis imperfectaCaffey diseasePotential roles in immune tolerance and plasma cell disorders (based on expression/function data)Other (evidence of involvement in secretory cell physiology and disease is emerging)
05
Safety considerations
Non-specific inhibition of FKBP isomerases by drugs like tacrolimus and rapamycin may cause off-target effects[2][6]No FKBP11-specific clinical safety data reported
06
Interacting drugs
FK506 (tacrolimus)
1 more in the full profile.
Beyond the preview
Go deeper on Peptidyl-prolyl cis-trans isomerase FKBP11 (FKBP11).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Peptidyl-prolyl cis-trans isomerase FKBP11 (FKBP11).